COVID-19 Vaccine INO-4800 Demonstrates Neutralizing Antibody and T-Cell Immune Responses in Preclinical Models

COVID-19 Vaccine INO-4800 Demonstrates Neutralizing Antibody and T-Cell Immune Responses in Preclinical Models

Inovio Pharmaceuticals (Nasdaq: INO) reported recent preclinical data summaries for their COVID-19 DNA vaccine called INO-4800 demonstrating promising information. Namely, the sponsor’s tests demonstrated robust neutralizing antibody and T cell immune responses...

Pin It on Pinterest